Assessing therapeutically developed assays.
Risk classification of early-stage breast cancer patients by gene expression profiling can result in substantial drug cost savings. Economic analyses suggest that appropriate use of clinically validated molecular diagnostics offers the potential for cost savings and improved patient quality of life.
Kolesar
Jill M
JM
Analytical Instrumentation Laboratory for Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics, University of Wisconsin, Paul P. Carbone Comprehensive Cancer Center, Madison, USA.
D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003362:Cost-Benefit Analysis; D005260:Female; D020869:Gene Expression Profiling / Q000191:economics / Q000379:methods; D023281:Genomics / Q000191:economics / Q000639:trends*; D006801:Humans; D008495:Medical Oncology / Q000191:economics / Q000639:trends*; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000235:genetics / Q000473:pathology; D011379:Prognosis; D018570:Risk Assessment
D014408:Biomarkers, Tumor